Catalyst

Slingshot members are tracking this event:

Top-line results from Esperion's (ESPR) pivotal Phase 3 Study 3 (1002-046) of bempedoic acid in ASCVD patients on less than approved daily starting doses of statins (high CV risk patients considered statin intolerant) expected May 2018

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ESPR Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 03, 2018
Occurred Source:
Related Keywords Phase 3 Study, Bempedoic Acid, Ascvd, Statins, High Cv Risk